Cargando…

PBRM1 Deficiency Sensitizes Renal Cancer Cells to DNMT Inhibitor 5-Fluoro-2’-Deoxycytidine

PBRM1 is a tumor suppressor frequently mutated in clear cell renal cell carcinoma. However, no effective targeted therapies exist for ccRCC with PBRM1 loss. To identify novel therapeutic approaches to targeting PBRM1-deficient renal cancers, we employed a synthetic lethality compound screening in is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Di, Dong, Kai, Jiang, Aimin, Jiang, Shaoqin, Fu, Zhibin, Bao, Yewei, Huang, Fuzhao, Yang, Chenghua, Wang, Linhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204009/ https://www.ncbi.nlm.nih.gov/pubmed/35719970 http://dx.doi.org/10.3389/fonc.2022.870229

Ejemplares similares

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
por: Aili, Abudureyimujiang, et al.
Publicado: (2021)

Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma
por: Jiang, Aimin, et al.
Publicado: (2021)

Editorial: Establishment of marker models for molecular typing of renal cell carcinoma
por: Jiang, Aimin, et al.
Publicado: (2023)

Identification and Verification of m(7)G Modification Patterns and Characterization of Tumor Microenvironment Infiltration via Multi-Omics Analysis in Clear Cell Renal Cell Carcinoma
por: Dong, Kai, et al.
Publicado: (2022)

5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1
por: Maslov, Alexander Y., et al.
Publicado: (2012)

AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine
por: Tsai, Chiou-Tsun, et al.
Publicado: (2013)

Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
por: Morfouace, Marie, et al.
Publicado: (2015)

Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer
por: Zhang, Jili, et al.
Publicado: (2023)

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
por: Carril-Ajuria, Lucía, et al.
Publicado: (2019)

2’-Fluoro-2’-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705
por: Yu, Peifa, et al.
Publicado: (2020)

3,3’-Diindolylmethane Enhances Paclitaxel Sensitivity by Suppressing DNMT1-Mediated KLF4 Methylation in Breast Cancer
por: Xiang, Fenfen, et al.
Publicado: (2021)

DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma
por: Bao, Yewei, et al.
Publicado: (2021)

PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth
por: Cai, Weijia, et al.
Publicado: (2019)

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)
por: Momparler, Richard L.
Publicado: (2013)

Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis
por: Espana-Agusti, Judit, et al.
Publicado: (2017)

Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme
por: Patel, Katan, et al.
Publicado: (2010)

Aza-deoxycytidine induces apoptosis or differentiation via DNMT3B and targets embryonal carcinoma cells but not their differentiated derivatives
por: Wongtrakoongate, P, et al.
Publicado: (2014)

Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis
por: Jiang, Aimin, et al.
Publicado: (2022)

Sohlh2 Inhibits the Malignant Progression of Renal Cell Carcinoma by Upregulating Klotho via DNMT3a
por: Liu, Yang, et al.
Publicado: (2022)

PBRM1 Regulates Stress Response in Epithelial Cells
por: Porter, Elizabeth G., et al.
Publicado: (2019)

TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models
por: Yang, Sherry X., et al.
Publicado: (2021)

Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma
por: Murakami, A, et al.
Publicado: (2017)

5-Fluoro-2′-deoxycytidine as a Probe for the Study of B/Z-DNA Transition by (19)F NMR Spectroscopy
por: Solodinin, Andrei, et al.
Publicado: (2019)

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
por: Varela, Ignacio, et al.
Publicado: (2011)

PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma
por: Chowdhury, Basudev, et al.
Publicado: (2016)

PBRM1 deficiency oncogenic addiction is associated with activated AKT–mTOR signalling and aerobic glycolysis in clear cell renal cell carcinoma cells
por: Tang, Yu, et al.
Publicado: (2022)

PBRM1 bromodomains associate with RNA to facilitate chromatin association
por: De Silva, Saumya M, et al.
Publicado: (2023)

Comparison of Antiviral Activity of Gemcitabine with 2′-Fluoro-2′-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2
por: Jang, Yejin, et al.
Publicado: (2021)

Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma
por: Zhou, Zhiyi, et al.
Publicado: (2022)

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
por: Liu, Xian-De, et al.
Publicado: (2020)

Development and validation of a PBRM1‐associated immune prognostic model for clear cell renal cell carcinoma
por: Chen, Jiayi, et al.
Publicado: (2021)

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells
por: Momparler, Richard L., et al.
Publicado: (2017)

Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2′-Deoxycytidine Against Pancreatic Cancer
por: Kong, Rui, et al.
Publicado: (2020)

Role of the Pbrm1 subunit and the PBAF complex in Schwann cell development
por: Polanetzki, Vanessa, et al.
Publicado: (2022)

A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors
por: Liu, Jin, et al.
Publicado: (2022)

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
por: Dai, Jiali, et al.
Publicado: (2023)

The epigenetic impact of suberohydroxamic acid and 5-Aza-2′-deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL-6 expression
por: Smesny Trtkova, Katerina, et al.
Publicado: (2022)

DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders
por: Sato, Hanae, et al.
Publicado: (2016)

Case report: biallelic DNMT3A mutations in acute myeloid leukemia
por: Cumbo, Cosimo, et al.
Publicado: (2023)

PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest
por: Huang, Li, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_50lqsg11jfd488ckom9lrqhlda